Phase I study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: Safety and tolerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback